Drug Profile

Research programme: Lysosomal storage disease therapeutics - bioOasis/Takeda

Latest Information Update: 06 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shire
Developer biOasis Technologies; Shire
Class Drug conjugates; Enzymes
Mechanism of Action Biological transport stimulants; Enzyme replacements; Transferrin receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

20 Jun 2023 Discontinued for Lysosomal storage diseases in Canada (Parenteral) before June 2023
20 Jun 2023 Discontinued for Lysosomal storage diseases in USA (Parenteral) before June 2023
08 Jan 2019 Shire has been acquired and merged into Takeda

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com